Plus Therapeutics introduced its CNSide cerebrospinal fluid diagnostics platform into the U.S. market, secured a first national coverage agreement...

Ardelyx posted third-quarter 2025 revenue of $110.3 million, anchored by a sharp acceleration in IBSRELA, which delivered $78.2 million,...

TME Pharma has published its half-year results and outlined a restructuring that shifts the micro-cap biotech to an outsourced,...

Nurix Therapeutics will step onto the investor stage in November, with its president and CEO slated for fireside chats...

Amneal Pharmaceuticals posted third-quarter 2025 revenue of $785 million, up 12% year over year, and nudged its full-year outlook...

NovaBridge’s ophthalmology subsidiary, Visara, has assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacturing, and commercialization...

Cytek Biosciences has launched a two-part initiative with the International Society for Advancement of Cytometry to widen access to...

BridgeBio reported third-quarter revenue of $120.7 million, fueled by $108.1 million in U.S. net product sales of Attruby (acoramidis)...

Roche has secured control of 89bio through a completed tender offer at 14.50 dollars per share in cash plus...

Argenx reported a pivotal third quarter: $1.13 billion in global net product sales, driven by the Vyvgart franchise across...